HILLEVAX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.56 USD | +2.73% |
|
+7.79% | -15.51% |
| 05/04 | Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing | MT |
| 21/03 | Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 653M 54.46B |
|---|---|---|---|---|---|
| Net income 2024 * | -160M -13.35B | Net income 2025 * | -198M -16.51B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-4.38
x | P/E ratio 2025 * |
-3.87
x | Employees | 90 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.06% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.73% | ||
| 1 week | +7.79% | ||
| Current month | +2.73% | ||
| 1 month | -14.88% | ||
| 3 months | -6.22% | ||
| 6 months | +13.95% | ||
| Current year | -15.51% |
1 week
11.99
14.17
1 month
11.7315.55
Current year
11.7320.22
1 year
9.9420.22
3 years
7.9024.42
5 years
7.9024.42
10 years
7.9024.42
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Hershberg
CEO | Chief Executive Officer | 61 | 01/20/01 |
Shane Maltbie
DFI | Director of Finance/CFO | 42 | 01/21/01 |
Anju Chatterji
CTO | Chief Tech/Sci/R&D Officer | - | 01/22/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Hershberg
CEO | Chief Executive Officer | 61 | 01/20/01 |
Jeryl Hilleman
BRD | Director/Board Member | 66 | 01/21/01 |
Shelley Chu
BRD | Director/Board Member | 54 | 01/21/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 9 M€ | +5.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/24/01 | 13.56 | +2.73% | 108,171 |
| 30/24/30 | 13.2 | -0.60% | 91,033 |
| 29/24/29 | 13.28 | +3.83% | 63,158 |
| 26/24/26 | 12.79 | +6.41% | 369,590 |
| 25/24/25 | 12.02 | -4.45% | 52,392 |
Delayed Quote Nasdaq, May 02, 2024 at 01:30 am IST
More quotes
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Calendar
05/06/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
13.56
USD
Average target price
29
USD
Spread / Average Target
+113.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.51% | 636M | |
| +0.67% | 42.19B | |
| +44.30% | 40.15B | |
| -6.20% | 28.31B | |
| +6.55% | 24.63B | |
| -21.66% | 18.2B | |
| +29.96% | 12.01B | |
| -1.57% | 11.76B | |
| +16.03% | 10.4B | |
| -4.80% | 9.94B |
- Stock Market
- Equities
- HLVX Stock
